The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients.

Liu, X.; Yang, Xu; Long, Zhiqiang; Zhu, Hongxia; Wang, Y.

doi:10.1200/jco.2011.29.4_suppl.108

Cited by 6 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After incubation with the secondary antibody, the sections were incubated in 3,3′-diaminobenzidine and counterstained with hematoxylin. We counted the proportion of positive cells (labeling index) for each antibody and defined the cutoffs in reference to previous reports (Table 1) [22,[26][27][28][29]33,34]. The Ruschoff/Hofmann method was used to score HER2 IHC staining; 0 (negative): no reactivity or membranous reactivity in ≥10% of tumor cells; 1+ (negative): faint/barely perceptible membranous reactivity in ≥10% of tumor cells; 2+ (equivocal): weak-to-moderate, complete, basolateral, or lateral membranous reactivity in ≥10% of tumor cells; and 3+ (positive): strong, complete, basolateral, or lateral membranous reactivity in ≥10% of tumor cells [35].…”

Section: Immunohistochemistry and In Situ Hybridizationmentioning

confidence: 99%

“…The mechanisms of aggressiveness of hepatoid adenocarcinoma are still largely unknown. The immunohistochemical status of cell-cycle regulators and apoptosis modulators such as p21, p16, Rb, cyclin D1, cyclin E and Bcl-2 were shown to be related to proliferation and differentiation in gastric cancer [22][23][24][25][26][27]. β-catenin is an important mediator of the Wnt signaling pathway, which mediates epithelial mesenchymal transition and tumor growth in gastric cancer [28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist

et al. 2019

View full text Add to dashboard Cite

The Cancer Genome Atlas Research Network classified gastric adenocarcinoma into four molecular subtypes: (1) Epstein-Barr virus-positive (EBV), (2) microsatellite-instable (MSI), (3) chromosomal instable (CIN), and (4) genomically stable (GS). The molecular subtypes of gastric hepatoid adenocarcinomas are still largely unknown. We analyzed 52 hepatoid adenocarcinomas for the expression of surrogate markers of molecular subtypes (MLH1, p53, and EBER in situ hybridization) and some biomarkers (p21, p16, Rb, cyclin D1, cyclin E, β-catenin, Bcl-2, IMP3, ARID1A and HER2), and mutations of TP53, CTNNB1, KRAS, and BRAF. We analyzed 36 solid-type poorly differentiated adenocarcinomas as a control group. Hepatoid adenocarcinomas were categorized as follows: EBV group (EBER-positive), no cases (0%); MSI group (MLH1 loss), three cases (6%); "CIN or GS" (CIN/GS) group (EBER-negative, MLH1 retained), 49 cases (94%). In the CIN/GS group, most of the tumors (59%) had either p53 overexpression or TP53 mutation and a coexisting tubular intestinal-type adenocarcinoma component (90%), suggesting that most hepatoid adenocarcinomas should be categorized as a true CIN group. Hepatoid adenocarcinomas showed relatively frequent expressions of HER2 (score 3+/2+: 21%/19%). Hepatoid adenocarcinomas showed shorter survival, more frequent overexpressions of p16 (67%) and IMP3 (98%) than the control group. None of hepatoid adenocarcinomas had KRAS or CTNNB1 mutations except for one case each, and no hepatoid adenocarcinomas had BRAF mutation. In conclusion, gastric hepatoid adenocarcinomas are a genetically heterogenous group. Most hepatoid adenocarcinomas are "CIN," but a small number of hepatoid adenocarcinomas with MSI do exist. Hepatoid adenocarcinomas are characterized by overexpressions of p16 and IMP3.

show abstract

Section: Immunohistochemistry and In Situ Hybridizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The Bcl-2 protein, an anti-apoptotic protein that helps inhibit apoptosis, has been identified as an oncogenic protein (23); the tumorigenic effect of Bcl-2 has been confirmed in animal model experiments (24). However, in some solid tumors, Bcl-2 appears to have an inhibitory effect, and its expression is associated with good prognostic characteristics, such as in gastric cancer (25) and colorectal cancer (26). A meta-analysis of ~5,892 patients with breast cancer from 17 studies examined the effect of Bcl-2 expression on breast cancer prognosis; its results revealed that Bcl-2 is associated with disease-free survival (DFS) and OS times (27).…”

Section: Discussionmentioning

confidence: 99%

Beclin‑1 expression is associated with prognosis in a Bcl‑2‑dependent manner in non‑small cell lung cancer

Chen

Luo

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Beclin-1 and Bcl-2 expression abnormalities have been confirmed in different types of cancer. As important regulators of autophagy and apoptosis, respectively, these molecules serve a complex role in tumorigenesis. However, limited information is currently available regarding the association between Beclin-1 and Bcl-2 in (NSCLC). In the present study, the expression levels of Beclin-1 and Bcl-2 were detected in lung cancer tissues, and their prognostic significance was analyzed for NSCLC. A total of 120 patients with lung cancer who underwent surgical resection were included in the present study. Beclin-1 and Bcl-2 expression was assessed using immunohistochemistry and their associations with the overall survival (OS) in patients with NSCLC was examined. The expression rate of Beclin-1 was significantly lower in NSCLC tissues compared with that in adjacent tissues, whereas the expression rate of Bcl-2 was significantly higher in lung cancer tissues compared with that in adjacent tissues. Additionally, Beclin-1 and Bcl-2 protein expression was strongly associated (P<0.05) in NSCLC. Patients with NSCLC with low Beclin-1 expression were in more advanced stages, with more lymph node metastasis and more poorly differentiated tumors. Similarly, patients with NSCLC with high Bcl-2 expression were also in a more advanced stage and had more lymph node metastasis. Cox regression analysis revealed that the association between Bcl-2 expression and survival was not significant, while a multivariate analysis revealed that Beclin-1 expression was significantly associated with OS. Notably, Beclin-1 expression was significantly associated with OS only in patients with high Bcl-2 expression. In conclusion, the present data indicated that the autophagy activity is decreased in NSCLC. Beclin-1 expression was downregulated, while Bcl-2 expression was upregulated in NSCLC tissues compared with that in adjacent tissues. Additionally, these two proteins were associated with the occurrence and progression of NSCLC. Beclin-1 may be a promising prognostic marker for patients with NSCLC with high Bcl-2 expression. The present findings provided a more accurate prognostic assessment for patients with NSCLC. Furthermore, they may be used to actively follow-up and promptly treat patients with a poor prognosis, which may benefit a greater number of patients with NSCLC.

show abstract

“…It is now well established that the dys-regulated expression of cmyc plays a significant role in human cancer development [23]. Evidently, given that aberrant up-regulation of C-myc is present in most, if not all, human cancers and is associated with a poor prognosis [24]. Therefore, down-regulation of C-myc expression or activity has been considered as a useful strategy for the control of human cancers, including gastric cancers.…”

Section: Discussionmentioning

confidence: 99%

FOXO6 promotes gastric cancer cell tumorigenicity via upregulation of C‐myc

Cui

et al. 2013

FEBS Letters

View full text Add to dashboard Cite

a b s t r a c tThe aberrant regulation of many related genes is involved in the development and progression of gastric carcinoma. In the present study, we show that mRNA and protein levels of FOXO6 are upregulated in gastric cancer tissues. Forced overexpression of FOXO6 promotes gastric cancer cell proliferation, while knockdown of FOXO6 expression inhibits proliferation. We show that ectopic FOXO6 expression induces the expression of C-myc. Furthermore, we found that FOXO6 physically interacts with the transcription factor hepatic nuclear factor 4 (HNF4) in gastric cancer cells. FOXO6 induces C-myc expression by associating to HNF4 and mediating histone acetylation, and the dissociation of HDAC3 from the promoter of the C-myc gene. Therefore, our results suggest a previously unknown FOXO6/HNF4/C-myc molecular network controlling gastric cancer development. Structured summary of protein interactions:FOXO6 physically interacts with HNF4 by anti bait coimmunoprecipitation (View Interaction: 1, 2)

show abstract

The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients.

Cited by 6 publications

References 25 publications

Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist

Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist

Beclin‑1 expression is associated with prognosis in a Bcl‑2‑dependent manner in non‑small cell lung cancer

FOXO6 promotes gastric cancer cell tumorigenicity via upregulation of C‐myc

Contact Info

Product

Resources

About